BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone919-859-1302
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.19 million
Profitability
Miscellaneous
Employees85
OptionableOptionable
BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions
What is BioCryst Pharmaceuticals' stock symbol?
BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."
How were BioCryst Pharmaceuticals' earnings last quarter?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.05. The biotechnology company earned $12.49 million during the quarter, compared to analyst estimates of $3.80 million. BioCryst Pharmaceuticals had a negative net margin of 428.00% and a negative return on equity of 141.00%. View BioCryst Pharmaceuticals' Earnings History.
When is BioCryst Pharmaceuticals' next earnings date?
What price target have analysts set for BCRX?
8 analysts have issued 12-month price targets for BioCryst Pharmaceuticals' stock. Their forecasts range from $8.50 to $16.00. On average, they expect BioCryst Pharmaceuticals' stock price to reach $12.9167 in the next twelve months. This suggests a possible upside of 43.5% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.
What is the consensus analysts' recommendation for BioCryst Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.
Has BioCryst Pharmaceuticals been receiving favorable news coverage?
News coverage about BCRX stock has trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the next several days.
Who are some of BioCryst Pharmaceuticals' key competitors?
Some companies that are related to BioCryst Pharmaceuticals include Allogene Therapeutics (ALLO), Ablynx (ABLYF), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA) and Alector (ALEC).
Who are BioCryst Pharmaceuticals' key executives?
BioCryst Pharmaceuticals' management team includes the folowing people:
- Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
- Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
- Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
- Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
- Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)
Who are BioCryst Pharmaceuticals' major shareholders?
BioCryst Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (9.72%), BlackRock Inc. (8.07%), Great Point Partners LLC (6.95%), Jennison Associates LLC (3.46%), D. E. Shaw & Co. Inc. (1.37%) and Northern Trust Corp (1.23%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Fred E Cohen, Lynne Powell, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals.
Which institutional investors are selling BioCryst Pharmaceuticals stock?
BCRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Great Point Partners LLC, D. E. Shaw & Co. Inc., Two Sigma Investments LP, Hudson Bay Capital Management LP, Royce & Associates LP, Jennison Associates LLC and Cheyne Capital Management UK LLP. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Alane P Barnes, Lynne Powell, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.
Which institutional investors are buying BioCryst Pharmaceuticals stock?
BCRX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Emory University, Bank of New York Mellon Corp, Geode Capital Management LLC, BlackRock Inc., Rhumbline Advisers, Metropolitan Life Insurance Co. NY and California Public Employees Retirement System. View Insider Buying and Selling for BioCryst Pharmaceuticals.
How do I buy shares of BioCryst Pharmaceuticals?
Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioCryst Pharmaceuticals' stock price today?
One share of BCRX stock can currently be purchased for approximately $9.00.
How big of a company is BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals has a market capitalization of $986.77 million and generates $25.19 million in revenue each year. The biotechnology company earns $-65,780,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. BioCryst Pharmaceuticals employs 85 workers across the globe.
What is BioCryst Pharmaceuticals' official website?
How can I contact BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]
MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
